Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly advancing and iShares Biotechnology ETF (IBB) down 0.2%.
Alumis (ALMS) stock was down more than 10% after the company reported that its Q1 revenue slumped to $1.7 million from $17.4 million a year earlier.
ARS Pharmaceuticals (SPRY) shares were down more than 20% after the company posted a wider Q1 net loss.
Aardvark Therapeutics (AARD) stock was down more than 33% after the company said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.